June 10: The Week in Cancer News
Patients who lose weight through bariatric surgery have a lower cancer risk, and a HER2-targeted therapy gets striking results in HER2-low breast cancer patients.
Progress Against Cancer
Patients who lose weight through bariatric surgery have a lower cancer risk, and a HER2-targeted therapy gets striking results in HER2-low breast cancer patients.
Contrast dye shortage delays scans for cancer, and more public assistance linked to higher survival rates for Black cancer patients.
The FDA has approved an immunotherapy to be used in combination with another immunotherapy or chemotherapy for the treatment of esophageal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved the...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisagenlecleucel (Kymriah) for certain adult patients...
A blood test could help determine who benefits from checkpoint inhibitors in lung cancer, and the FDA approves a drug combination for certain patients with acute myeloid leukemia.
The FDA approved a new regimen that includes a molecularly targeted therapeutic for some older leukemia patients not eligible for intensive chemotherapy. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) in...
The FDA approved the chemotherapeutic azacitidine for patients with juvenile myelomonocytic leukemia The U.S. Food and Drug Administration (FDA) has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Azacitidine...
Esophageal cancer increases in the middle-aged and more from this week in cancer news.
New studies shine a light on the effects of a cancer diagnosis on mental health and suicide risk.
First child to receive CAR T-cell therapy celebrates 10 years cancer-free, and authorization denials delay treatment for patients with Medicare Advantage.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More